The Food and Drug Administration (FDA) has granted accelerated approval to Voyxact ® (sibeprenlimab-szsi) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for ...

The FDA’s Priority Review designation allows for a shortened review period (within 6 months) from the time of application acceptance.

GLP-1 RA use with subsequent prepregnancy or early pregnancy discontinuation linked to higher risk for preterm delivery, gestational diabetes ...

Association strongest for those with cannabis use disorder compared with cannabis users without abuse or dependence or nonusers.

March of Dimes report shows high rates of preterm birth, infant mortality, as well as worsening sociodemographic disparities.

Findings from the phase 3 MATTERHORN trial supported the FDA approval of perioperative durvalumab for resectable gastric and GEJ cancers.

Extensive safety testing and manufacturing improvements have now made it possible to bring the drug back to the US market.

Childhood exposure linked to modestly better cognition in secondary school, but no significant difference seen at age ~60 years.

HealthDay News — Eli Lilly reached a major milestone Friday, becoming the first healthcare company in the world to hit a $1 trillion market value. The drug company briefly crossed the trillion-dollar ...

New postmarketing reports link Adzynma to neutralizing antibodies and a fatality, leading the FDA to evaluate the need for updated labeling.

Benefits of metformin outweigh risks among young people with overweight or obesity and treated with second-gen antipsychotics.

Based on the efficacy results, Novo Nordisk has made the decision to discontinue the 1-year extension periods for these trials.